Andrew Koren

847 total citations · 1 hit paper
33 papers, 600 citations indexed

About

Andrew Koren is a scholar working on Surgery, Economics and Econometrics and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Andrew Koren has authored 33 papers receiving a total of 600 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Surgery, 14 papers in Economics and Econometrics and 12 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Andrew Koren's work include Lipoproteins and Cardiovascular Health (17 papers), Health Systems, Economic Evaluations, Quality of Life (13 papers) and Pharmaceutical Economics and Policy (11 papers). Andrew Koren is often cited by papers focused on Lipoproteins and Cardiovascular Health (17 papers), Health Systems, Economic Evaluations, Quality of Life (13 papers) and Pharmaceutical Economics and Policy (11 papers). Andrew Koren collaborates with scholars based in United States, France and Canada. Andrew Koren's co-authors include Michael J. Louie, Anne C. Goldberg, Eric D. Peterson, Ann Marie Návar, Salim S. Virani, Jennifer G. Robinson, Zhuokai Li, Tracy Y. Wang, Véronique L. Roger and Peter W.F. Wilson and has published in prestigious journals such as Circulation, Kidney International and The American Journal of Cardiology.

In The Last Decade

Andrew Koren

33 papers receiving 591 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sex Differences in the Use of Statins in Community Practice

2019 197 citations Tracy Y. Wang, Anne C. Goldberg et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrew Koren United States	12	368	212	200	119	53	33	600
L. Veronica Lee United States	11	373 1.0×	261 1.2×	112 0.6×	91 0.8×	43 0.8×	13	503
Juan Verdejo Mexico	11	354 1.0×	172 0.8×	249 1.2×	133 1.1×	32 0.6×	15	576
Vasilisa Sazonov United States	13	315 0.9×	143 0.7×	128 0.6×	191 1.6×	28 0.5×	23	526
Joseph Elassal United States	11	231 0.6×	154 0.7×	131 0.7×	77 0.6×	41 0.8×	16	456
Elias Basayannis Greece	3	338 0.9×	170 0.8×	119 0.6×	136 1.1×	14 0.3×	5	425
Dominik Lautsch United States	14	391 1.1×	203 1.0×	299 1.5×	229 1.9×	14 0.3×	73	639
Annemarie Armani United States	8	305 0.8×	72 0.3×	155 0.8×	215 1.8×	28 0.5×	14	585
Jane K. Stock France	9	263 0.7×	95 0.4×	92 0.5×	90 0.8×	36 0.7×	40	436
Charlotte Jones-Burton United States	12	184 0.5×	95 0.4×	108 0.5×	64 0.5×	66 1.2×	22	482
Benjamin J. Hirsh United States	13	264 0.7×	74 0.3×	341 1.7×	162 1.4×	36 0.7×	23	764

Countries citing papers authored by Andrew Koren

Since Specialization

Citations

This map shows the geographic impact of Andrew Koren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Koren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Koren more than expected).

Fields of papers citing papers by Andrew Koren

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Koren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Koren. The network helps show where Andrew Koren may publish in the future.

Co-authorship network of co-authors of Andrew Koren

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Koren. A scholar is included among the top collaborators of Andrew Koren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Koren. Andrew Koren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lowenstern, Angela, Shuang Li, Salim S. Virani, et al.. (2020). Beliefs, risk perceptions, and lipid management among patients with and without diabetes: Results from the PALM registry. American Heart Journal. 225. 88–96. 6 indexed citations

Ha, Andrew C.T., John A. Stewart, George J. Klein, et al.. (2020). Impact of electrical cardioversion on quality of life for patients with symptomatic persistent atrial fibrillation: Is there a treatment expectation effect?. American Heart Journal. 226. 152–160. 5 indexed citations

Crijns, Harry J.G.M., et al.. (2020). Dronedarone treatment following cardioversion in patients with atrial fibrillation/flutter: A post hoc analysis of the EURIDIS and ADONIS trials. Journal of Cardiovascular Electrophysiology. 31(5). 1022–1030. 2 indexed citations

Blomström‐Lundqvist, Carina, Nassir F. Marrouche, Stuart J. Connolly, et al.. (2020). Efficacy and safety of dronedarone by atrial fibrillation history duration: Insights from theATHENAstudy. Clinical Cardiology. 43(12). 1469–1477. 10 indexed citations

Vámos, Máté, Hugh Calkins, Peter R. Kowey, et al.. (2019). Efficacy and safety of dronedarone in patients with a prior ablation for atrial fibrillation/flutter: Insights from the ATHENA study. Clinical Cardiology. 43(3). 291–297. 7 indexed citations

Ginsberg, Henry N., Jaakko Tuomilehto, G. Kees Hovingh, et al.. (2019). Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia. Cardiovascular Drugs and Therapy. 33(1). 69–76. 9 indexed citations

Ferdinand, Keith C., Terry A. Jacobson, Andrew Koren, et al.. (2019). Alirocumab efficacy and safety by race and ethnicity: Analysis from 3 ODYSSEY phase 3 trials. Journal of clinical lipidology. 13(4). 586–593.e5. 10 indexed citations

Glueck, Charles J., Alan S. Brown, Anne C. Goldberg, et al.. (2018). Alirocumab in high-risk patients: Observations from the open-label expanded use program. Journal of clinical lipidology. 12(3). 662–668. 10 indexed citations

Tóth, Peter P., Jamie P. Dwyer, Christopher P. Cannon, et al.. (2018). Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney International. 93(6). 1397–1408. 79 indexed citations

10.

McCullough, Peter A., Christie M. Ballantyne, Santosh K. Sanganalmath, et al.. (2018). Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials). The American Journal of Cardiology. 121(8). 940–948. 14 indexed citations

11.

Jacobson, Terry A., et al.. (2016). Development and Content Validation of a Patient-Reported Outcome Measure to Evaluate Statin Intolerance in the Real World. Value in Health. 19(3). A52–A52. 1 indexed citations

12.

Schulman, Kathy L., Lois Lamerato, Mehul Dalal, et al.. (2016). Development and Validation of Algorithms to Identify Statin Intolerance in a US Administrative Database. Value in Health. 19(6). 852–860. 12 indexed citations

13.

Lamerato, Lois, et al.. (2015). DEVELOPMENT AND VALIDATION OF ALGORITHMS TO IDENTIFY STATIN INTOLERANCE IN A US ADMINISTRATIVE DATABASE. Value in Health. 18(3). A2–A2. 1 indexed citations

14.

Ezekowitz, Michael D., Kenneth A. Ellenbogen, John Dimarco, et al.. (2015). A placebo-controlled, double-blind, randomized, multicenter study to assess the effects of dronedarone 400 mg twice daily for 12 weeks on atrial fibrillation burden in subjects with permanent pacemakers. Journal of Interventional Cardiac Electrophysiology. 42(2). 69–76. 11 indexed citations

15.

Panaccio, Mary, Charles Wentworth, Stephan Lanes, et al.. (2015). A common data model to assess cardiovascular hospitalization and mortality in atrial fibrillation patients using administrative claims and medical records. Clinical Epidemiology. 7. 77–77. 11 indexed citations

16.

Kim, Michael, Jay Lin, Mehul Jhaveri, & Andrew Koren. (2014). Impact of Dronedarone Treatment on Healthcare Resource Utilization in Patients with Atrial Fibrillation/Flutter. Advances in Therapy. 31(3). 318–332. 4 indexed citations

17.

Wu, Jasmanda, Wanju S. Dai, Andrew Koren, et al.. (2014). Assessment of Dronedarone Utilization Using US Claims Databases. Clinical Therapeutics. 36(2). 264–272.e2. 7 indexed citations

18.

Gao, Shujun, et al.. (2011). Evaluation of Dronedarone Use in the US Patient Population Between 2009 and 2010: A Descriptive Study Using a Claims Database. Clinical Therapeutics. 33(10). 1483–1490.e3. 5 indexed citations

19.

Koren, Andrew, et al.. (1996). Testicular feminization: radiologic considerations in a unique formof cryptorchidism. Abdominal Imaging. 21(3). 272–274. 5 indexed citations

20.

Koren, Andrew, et al.. (1983). [Postsplenectomy sepsis in children].. PubMed. 105(9). 252–4. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact